Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization.
Paul Friedman K, Gagne M, Loo LH, Karamertzanis P, Netzeva T, Sobanski T, Franzosa JA, Richard AM, Lougee RR, Gissi A, Lee JJ, Angrish M, Dorne JL, Foster S, Raffaele K, Bahadori T, Gwinn MR, Lambert J, Whelan M, Rasenberg M, Barton-Maclaren T, Thomas RS.
Paul Friedman K, et al. Among authors: gagne m.
Toxicol Sci. 2020 Jan 1;173(1):202-225. doi: 10.1093/toxsci/kfz201.
Toxicol Sci. 2020.
PMID: 31532525
Free PMC article.